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Impaired spermatogenesis, male reproductive
tract abnormalities such as hypospadias and
cryptorchidism, and testicular cancer have
been proposed to comprise a common under-
lying syndrome with a common aetiology
resulting from the disruption of embryonic
programming and gonadal development dur-
ing fetal life, termed the testicular dysgenesis
syndrome (TDS) (Sharpe and Skakkebaek
2003; Skakkebaek et al. 2001). A hormonal
etiology most likely underlies this syndrome,
although it is believed to have more than one
cause, possibly including other than endocrine
disruption. Some common causes of endocrine
disruption include infection, diet and body
weight, lifestyle, genetics, and environmental
exposure, but endocrine-disrupting chemicals
(EDCs), particularly those with estrogen-
like properties, have received the most
scientific attention. 
The synthetic estrogenic drug diethyl-
stilbestrol (DES) was prescribed to more than
5 million pregnant women from the late 1940s
to the early 1970s to prevent abortions and
pregnancy-related complications (Palmlund
et al. 1993). Evidence later showed that
maternal ingestion of DES during early preg-
nancy increased the risk of vaginal clear cell
adenocarcinoma in female offspring (Herbst
et al. 1971) and resulted in an increased inci-
dence of malformations of the testes, the
development of epididymal cysts, and
impaired sperm quality in male offspring
(Bibbo et al. 1977). During pregnancy, mater-
nal estrogen levels are significantly elevated.
However, more than 90% of maternal endo-
genous estrogens are effectively sequestered via
binding to sex hormone binding globulin
(SHBG), and thus the fetus is relatively pro-
tected (Joffe 2001; Vidaeff and Sever 2005).
On the other hand, DES and ethinylestradiol
do not bind well to SHBG, having a higher
biopotency if ingested (Sharpe and Skakkebaek
2003; Vidaeff and Sever 2005). Additionally,
transgenerational exposure is also possible
when lipophilic xenoestrogens are mobilized
during pregnancy and lactation (Colborn
et al. 1993).
Previous systematic reviews of studies in
which pregnant women were exposed to
estrogens other than DES have failed to find
evidence of an increased risk of urogenital
abnormalities in the male offspring (Raman-
Wilms et al. 1995; Storgaard et al. 2006;
Toppari et al. 1996; Vidaeff and Sever 2005),
and have raised the possibility that nonestro-
genic or atypical estrogenic effects of DES
exposure in utero induce male reproductive
abnormalities. However, none of the effects
of DES exposure on either male or female
offspring of exposed wild-type pregnant mice
were induced when administered to ERKO
(ER-α knockout) mice (Couse et al. 2001),
strongly suggesting an ER-α–mediated mech-
anism. There is, however, a body of experi-
mental data that is consistent with an effect of
antiandrogenic industrial chemicals on male
sexual differentiation (Gray et al. 1999,
2000). Moreover, mechanisms other than
endocrine disruption may be involved in tes-
ticular toxicity; for example, the nematocide
dibromochloropropane, an alkylating agent,
is one of the most potent known testicular
toxins in adults (Joffe 2001). In this review
we focus on the estrogen hypothesis of TDS.
Although several systematic reviews of the
literature on the association between estro-
genic agents and the disorders thought to
belong to the TDS have been published, they
are predominantly qualitative and the only
quantitative summary estimate of the associa-
tion between prenatal exposure to estrogenic
agents and testicular cancer was published
over 10 years ago (Toppari et al. 1996). The
primary objective of a quantitative meta-
analysis is to combine the results of previous
studies examining a specific research question
to arrive at a summary conclusion about a
body of research. It has been found particu-
larly useful when individual studies are too
small to yield a valid conclusion, but it can-
not, however, correct for bias and confound-
ing. When applied to observational studies,
subset analysis can be a useful tool to explore
the reasons for discrepancies among the
results of different studies. 
The objectives of this research were there-
fore to carry out a quantitative meta-analysis of
the association between three of the end points
related to TDS and prenatal exposure to estro-
genic agents that would account for both the
size and quality of the studies included and
yield updated summary estimates in light of
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BACKGROUND: Male reproductive tract abnormalities such as hypospadias and cryptorchidism, and
testicular cancer have been proposed to comprise a common syndrome together with impaired sper-
matogenesis with a common etiology resulting from the disruption of gonadal development during
fetal life, the testicular dysgenesis syndrome (TDS). The hypothesis that in utero exposure to estro-
genic agents could induce these disorders was first proposed in 1993. The only quantitative sum-
mary estimate of the association between prenatal exposure to estrogenic agents and testicular
cancer was published over 10 years ago, and other systematic reviews of the association between
estrogenic compounds, other than the potent pharmaceutical estrogen diethylstilbestrol (DES), and
TDS end points have remained inconclusive. 
OBJECTIVES: We conducted a quantitative meta-analysis of the association between the end points
related to TDS and prenatal exposure to estrogenic agents. Inclusion in this analysis was based on
mechanistic criteria, and the plausibility of an estrogen receptor (ER)-α–mediated mode of action
was specifically explored. 
RESULTS: We included in this meta-analysis eight studies investigating the etiology of hypospadias
and/or cryptorchidism that had not been identified in previous systematic reviews. Four additional
studies of pharmaceutical estrogens yielded a statistically significant updated summary estimate for
testicular cancer. 
CONCLUSIONS: The doubling of the risk ratios for all three end points investigated after DES expo-
sure is consistent with a shared etiology and the TDS hypothesis but does not constitute evidence
of an estrogenic mode of action. Results of the subset analyses point to the existence of unidentified
sources of heterogeneity between studies or within the study population.
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the body of research carried out since the for-
mulation of the estrogen hypothesis. Inclusion
in this analysis was based on mechanistic crite-
ria, and the plausibility of an ER-α–mediated
mode of action was specifically explored.
Moreover, subset analysis has been applied to
categories of compounds with estrogenic
potencies differing by several orders of magni-
tude in an attempt to detect the existence of
any potency–response trend. Most of the stud-
ies of sperm quantity or quality have been
concerned with time trends rather than etiol-
ogy, and this end point was not considered
further here.
Material and Methods
Identification and selection of literature. A
computerized search was conducted using the
databases PubMed (National Center for
Biotechnology Information 2007) and Web of
Science (ISI Web of Knowledge 2007) for the
period 1970 to April 2007. The general search
keywords were “estrogen,” “risk,” “dose,” and
either “hypospadias,” “cryptorchidism,” or
“testicular cancer.” A preliminary identifica-
tion was performed by screening the titles and,
if relevant, the abstracts of retrieved literature.
The next stage was to check the citations and
references of selected studies. This was an iter-
ative process, repeated until no new study
could be identified. A set of both inclusion
and exclusion criteria was defined, and all rele-
vant literature was then checked for eligibility.
The inclusion criteria considered were a) study
design, namely, either a case–control, cohort,
or clinical trial; b) written in English; c) expo-
sure to one or a mixture of known estrogenic
compounds; and d) sufficient data reported to
be used in meta-analysis.
The following exclusion criteria were used:
• Exposure to a group of compounds (sus-
pected endocrine disruptors) for which
mode of action was unspecified, for exam-
ple, pesticides.
• Studies of exposure to phytoestrogens.
Some phytoestrogens have been found to
have a greater binding affinity for ER-β
than for ER-α and can result in agonistic or
antagonistic effects (Mueller et al. 2004).
• Studies of maternal endogenous hormones. 
• Studies of the same cohort as this would bias
the results towards the particular studies.
• Incomplete data.
Data extraction and quality rating. In
addition to the number of exposed and non-
exposed cases and controls, and risk ratios
(RRs) with their confidence intervals (CIs),
information regarding the study design, estro-
genic agent, geographic location of the study,
and year of publication were extracted from
the selected literature to allow subset analysis
to be carried out. When more than one RR
was reported, the following priorities were set
for choice:
• Adjusted RRs were used, except when the
study provided only unadjusted estimates.
• When multiple estimates were given, the
RR estimator on which the authors had
relied for their assessment of causal associa-
tion was used.
• Overall RRs were chosen instead of those
derived from further stratifications. If an
overall estimate was not provided, the RRs
of the maximum duration of exposure or
the maximum exposure concentration were
chosen. 
Several aspects of the quality of each study
were also recorded according to a rating
scheme adapted from those previously
described (Altman 1991; Rushton 2000).
Every criterion was assessed on a scale of 0 to
2, 0 suggesting that it was not present, 1
when it was unclear, and 2 when that crite-
rion was satisfied. A maximum score of 50
and 52 could be assigned for retrospective
(case–control) and prospective (cohort and
clinical trials) studies, respectively. This
enabled a quality sensitivity analysis to be per-
formed to check the influence of studies with
low quality on the pooled estimate. 
Data analysis. Graphical representation.
The RRs and CIs were plotted against the year
of publication to determine whether any posi-
tive or negative trends in reporting RRs had
occurred over time. Similarly, quality scores
were plotted against the year of publication to
investigate whether the quality of studies
improved over time. To assess publication
bias, a funnel plot (SE vs. RR) was produced
based on the assumption that smaller studies
are less precise in their RRs and thus have less
weight and larger SE and should scatter more
widely at the lower end of the graph, whereas
larger studies will tend to be closer together
(Sterne et al. 2001). Forest plots present the
RRs against the reference of the study and
help check homogeneity visually.
Statistical pooling. Pooled estimates and
95% CIs were calculated using both a fixed-
effects model (Mantel–Haenszel method) and
a random-effects model (DerSimonian–Laird
method), allowing evaluation of the depen-
dence of the conclusions of the analysis on the
model assumptions. A summary estimate is
considered statistically significant at the 0.05
level if its CI does not include unity.
The Mantel–Haenszel pooled effect esti-
mate was used in a chi-square statistical test of
homogeneity to assess the between-study vari-
ance. The magnitude of the test statistics
depends on the weight of each study. When
the number of studies is low or the studies
themselves are small, the test statistic Q tends
to be small. Tests of heterogeneity in meta-
analyses are generally low in their power to
reject the null hypothesis of homogeneity. For
this reason, the chi-square statistical test of
homogeneity was carried out at both 0.05 and
0.1 significance levels. Additionally, pooled
estimates calculated using fixed effect and
random effect models differ only if there is
lack of homogeneity between studies. The
estimates obtained by both methods were
therefore compared to better assess potential
heterogeneity between studies, in which case a
single summary estimate of effect may be con-
sidered inappropriate.
Subset and sensitivity analyses. To inves-
tigate potential sources of heterogeneity
between studies, we performed subset analyses
for the study design, estrogenic agent, and
geographic location.
Some studies exploring the influence of
hormonal treatment during pregnancy did not
specify the type of hormone. From what is
known of the hormonal treatment of common
conditions occurring during pregnancy, it was
deemed reasonable to assume that they would
have been likely to include estrogens, and
these studies were included in the analysis.
The validity of this assumption was tested by
applying stricter criteria and calculating a
summary estimate of effect excluding any
study in which the hormone used had not
been specified. Further sensitivity analysis was
performed by excluding low-quality studies
and extremes (exclusion of the studies with the
largest and smallest RR estimators and exclu-
sion of the studies with the largest and smallest
weights) to verify that either the quality of the
studies or one particular study did not have an
excessive influence on the pooled estimate. 
Results
A total of 50 studies were identified for the
association between in utero exposure to estro-
genic agents and hypospadias and/or cryp-
torchidism, including 16 that had not been
included in previous systematic reviews.
Sixteen studies, of which 8 were new studies,
were included in the calculation of a sum-
mary estimate of effect for either or both end
points (Table 1). Studies predating the for-
mulation of the TDS hypothesis often were
designed to explore the association of in utero
exposure to a range of pharmaceuticals with
birth malformations. Other than 2 recent
studies for which pesticide exposure was
determined by chemical analysis of specific
compounds, assessment of exposure to pesti-
cides is generally derived from the occupation
of the mother and specific agents are not
identified. 
Of the 12 studies identified for the associ-
ation with testicular cancer, only 3 were
excluded from the calculation of a summary
estimate of effect (Table 2).
Hypospadias. The data from studies
included in the meta-analysis for hypospadias
are summarized in Table 3. Three extreme val-
ues, two greater than and one lower than unity,
can be identified visually from the forest plot of
Martin et al.
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the RRs and their CIs (Figure 1). These
extremes correspond to studies with larger SEs,
and the shape given to the funnel plot
(Figure 2) by those smaller positive studies
would be consistent with publication bias.
These two extreme positive risk ratios were,
however, reported after what is commonly
referred to as “third-generation exposure” to
DES, when the mother herself had been
exposed to DES prenatally. It was recognized
that the inclusion of such studies in the meta-
analysis could have introduced heterogeneity,
and the influence of this choice was investi-
gated in the subset analysis. Plots of the quality
score and RRs versus year of publication did
Testicular dysgenesis syndrome meta-analysis
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Table 1. Studies identified for the association between in utero exposure to estrogenic agent and hypospadias and cryptorchidism.
Reference End point Comment Previous reviewsa
Aarskog 1970 Hypospadias Data on progestins treatment only
Beard et al. 1984 Cryptorchidism Included R-W, T, S
Beral and Colwell 1981 Cryptorchidism Study too small to calculate risk ratio Sx
Berkowitz and Lapinski 1996 Cryptorchidism Use of clomiphene before pregnancy recognized
Bernstein et al. 1988 Cryptorchidism Maternal endogenous hormones S
Bhatia et al. 2005 Cryptorchidism Included
Hypospadias Included
Bianca et al. 2003 Hypospadias Occupational exposure of fathers to pesticides
Burton et al. 1987 Cryptorchidism Maternal endogenous hormone levels S
Calzolari et al. 1986 Hypospadias Oral contraceptive use before pregnancy recognized R-Wx, S
Cosgrove et al. 1977 Cryptorchidism No control data for documented abnormalities R-Wx, Sx
Hypospadias
Czeizel et al. 1979 Hypospadias Progesterone treatment R-Wx
Czeizel et al. 1999 Cryptorchidism Ecological study design
Hypospadias
Davies et al. 1986 Cryptorchidism Oral contraceptive use before pregnancy recognized S
Depue 1984 Cryptorchidism Same cohort as Depue (1988) R-Wx, S
Depue 1988 Cryptorchidism Included
Flores-Luevano et al. 2003 Hypospadias Included
Garcia-Rodriguez et al. 1996 Cryptorchidism Ecological study design V, S
Gill et al. 1977 Cryptorchidism No genitourinary abnormalities in exposed infants T
Hypospadias
Gill et al. 1979 Cryptorchidism Cryptorchidism in men with testicular hypoplasia T, S
Harlap et al. 1975 Cryptorchidism All cases exposed to progesterone R-W
Hypospadias
Harlap and Eldor 1980 Cryptorchidism No cases after oral contraceptive use during pregnancy R-W
Hypospadias
Harlap et al. 1985 Cryptorchidism Included R-W
Hypospadias Included
Heinonen et al. 1977 Hypospadias Included
Hemminki et al. 1999 Hypospadias No exposed controls
Henderson et al. 1976 Cryptorchidism No unexposed cases T, V
Hypospadias No unexposed cases
Janerich et al. 1980 Hypospadias Data for hypospadias not reported R-Wx
Källén 1988 Hypospadias Included R-W
Källén and Winberg 1982 Hypospadias No exposed controls R-Wx, S
Källén et al. 1991 Hypospadias Included R-W, S
Key et al. 1996 Cryptorchidism No exogenous hormone use S
Klip et al. 2002 Hypospadias Included
Kristensen et al. 1997 Cryptorchidism Exposure to unspecified pesticides V, S
Longnecker et al. 2002 Cryptorchidism DDE is antiandrogenic V, S
Hypospadias
McBride et al. 1991 Cryptorchidism Included R-W, S
Monteleone-Neto et al. 1981 Hypospadias Included R-W, V, S
North and Golding 2000 Hypospadias Phytoestrogens S
Palmer et al. 2005 Hypospadias Included
Pierik et al. 2004 Cryptorchidism Phytoestrogens, unspecified pesticides, or EDCs
Hypospadias
Polednak and Janerich 1983 Hypospadias Included R-W, S
Pons et al. 2005 Hypospadias Included
Restrepo et al. 1990 Cryptorchidism Unspecified pesticides V
Rothman and Louik 1978 Hypospadias Oral contraceptive use before pregnancy recognized S
Sorensen et al. 2005 Hypospadias Clomiphene is estrogenic but does not act via ER
Stoll et al. 1990 Hypospadias Oral contraceptive use before pregnancy recognized R-Wx, S
Sweet et al. 1974 Hypospadias No exogenous estrogens during pregnancy R-W
Torfs et al. 1981 Cryptorchidism Same cohort as Bhatia et al. (2005) R-Wx
Hypospadias
Vessey et al. 1983 Cryptorchidism Included S
Hypospadias No unexposed cases S
Vrijheid et al. 2003 Hypospadias Included
Weidner et al. 1998 Cryptorchidism Exposure to unspecified pesticides V, S
Hypospadias
Whitehead and Leiter 1981 Cryptorchidism No controls T
aThe letters R-W, T, V, and S refer to Raman-Wilms et al. (1995), Toppari et al. (1996), Vidaeff and Sever (2005), and Storgaard et al. (2006), respectively, where the suffix “x” indicates
study was excluded from that review.
not suggest any significant trends in quality
of the studies or estimates of effect over time
(not shown).
The pooled estimates of effect by both the
Mantel–Haenszel and DerSimonian–Laird
methods are very close to unity, and no rela-
tionship between in utero exposure to estro-
genic agents and hypospadias could be
detected (Table 4). None of the chi-square
tests allowed the rejection of the null hypothe-
sis of homogeneity between the studies at the
0.05 or 0.1 level of statistical significance. The
subsets of studies in which exposure to DES
and pharmaceutical estrogens were investi-
gated yielded statistically significant risk ratios
with both models, although the modest dis-
crepancy between the fixed-effects and random-
effects estimates suggests heterogeneity.
Summary estimates for the latter subset were
no longer significant when studies that
included DES exposure were excluded.
Although these results were based on four
studies that all addressed in utero exposure to
oral contraceptives, some heterogeneity
between studies remained. Excluding the stud-
ies of third-generation exposure to DES, val-
ues for the summary estimate of effect were
found to be 1.33 (95% CI, 0.63–2.83) by the
Mantel–Haenszel method and 1.31 (95% CI,
0.52–3.26) by the DerSimonian–Laird
method, a very modest and nonsignificant
increase in risk. Excluding third-generation
exposure from the DES subset yielded esti-
mates of 2.02 (95% CI, 1.12–3.65) by the
Mantel–Haenszel method and 2.00 (95% CI,
0.97–4.15) by the DerSimonian–Laird
method, on the basis of two studies investigat-
ing exposure to any estrogenic drug during the
first trimester of pregnancy. The difference
between the results obtained by the two mod-
els for studies of third-generation exposure to
DES was reduced only slightly by excluding
the study by Klip et al. (2002); the Mantel–
Haenszel method yielded an estimate of 2.46
(95% CI, 0.91–6.67) and the DerSimonian–
Laird method of 2.18 (95% CI, 0.64–7.46).
The latter study’s cohort had been recruited in
a fertility clinic, and whether results obtained
with subfertile women are generalizable to all
women exposed to DES in utero has been
questioned (Hernandez-Diaz 2002). 
Although the equality of the results
obtained by both methods for the environ-
mental estrogens subset suggests those results
are robust, the influence of the weight of the
study by Vrijheid et al. (2003) cannot be
underestimated, as shown by the sensitivity
analysis. Exclusion of this study from the
analysis yielded a statistically significant
Mantel–Haenszel estimate but a lower and not
statistically significant DerSimonian–Laird
estimate, revealing heterogeneity. A statisti-
cally significant estimate was obtained for
prospective studies by the Mantel–Haenszel
method, but the wide difference with the esti-
mate using the random effect model was sug-
gestive of heterogeneity. Geographic subsets
point to a higher risk in Latin America,
although the pooled estimates for this location
were based on only two studies and did not
reach statistical significance.
Martin et al.
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Table 2. Studies identified for the association between in utero exposure to estrogenic agent and testicular
cancer.
Reference Comment Previous reviewsa
Brown et al. 1986 Included T, S
Depue et al. 1983 Included T, S
Dieckmann et al. 2001 Maternal endogenous hormone levels
Gershman and Stolley 1988 Included S
Hardell et al. 2004 Included
Hemminki et al. 1999 No cases
Henderson et al. 1979 Included T, S
Moss et al. 1986 Included T, S
Schottenfeld et al. 1980 Included T, S
Strohsnitter et al. 2001 Included S
Walcott et al. 2002 Phytoestrogens
Weir et al. 2000 Included S
aThe letters T and S stand for Toppari et al. (1994) and Storgaard et al. (2006), respectively.
Table 3. Summary of data used for the meta-analysis of the association between prenatal estrogenic agents and hypospadias. 
Cases Controls Quality
Reference Design Agent Location E NE E NE RR (95% CI) SE Weight score
Bhatia et al. 2005 Case–control DDT California, USA 9 34 42 117 0.79 (0.33–1.89) 0.38 7.07 41
Flores-Luevano et al. 2003 Case–control DDT Mexico City 8 33 5 23 1.13 (0.24–5.29) 0.65 2.39 37
Harlap et al. 1985 Cohort Oral contraceptives North Carolina, USA 3 98 847 32,597 1.10 (0.10–3.90) 0.64 2.47 36
Heinonen et al. 1977 Cohort Estrogenic drugs United States 4 184 295 25,069 1.60 (0.44–4.04) 0.69 2.12 45
Källén et al. 1988 Case–control Oral contraceptives Sweden 5 43 6 109 2.11 0.79 1.58 23
Källén et al. 1991 Case–control Oral contraceptives 8 countries 16 830 11 835 1.36 (0.64–2.92) 0.43 5.40 30
Klip et al. 2002 Cohort DES (mother exposed Netherlands 4 8 205 8,729 21.30 (6.50–70.10) 2.34 0.18 27
prenatally)
Monteleone-Neto et al. 1981 Case–control Sex hormones Latin America 21 252 12 307 2.20 (1.04–4.91) 0.44 5.11 24
Palmer et al. 2005 Cohort DES (mother exposed United States 10 3 2,522 1,336 1.70 (0.40–6.80) 0.72 1.95 36
prenatally)
Polednak and Janerich 1983 Case–control Oral contraceptives New York, USA 1 98 3 96 0.33 0.82 1.48 27
Pons et al. 2005 Case–control DES (mother exposed Paris, France 3 44 237 17,349 4.99 (1.20–16.80) 1.30 0.59 17
prenatally)
Vrijheid et al. 2003 Case–control Phthalates United Kingdom 147 3,324 1,399 31,092 0.90 (0.74–1.10) 0.09 129.31 31
(occupational)
Abbreviations: E, exposed; NE, nonexposed. 
Figure 1. Forest plot of the risk estimates and their
95% CIs from the studies included in the meta-
analysis of the association between prenatal expo-
sure to estrogenic agents and hypospadias.
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Figure 2. Funnel plot of the risk estimate studies
included in the meta-analysis of the association
between prenatal exposure to estrogenic agents
and hypospadias and their SEs.
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In addition to the results of the sensitivity
analysis presented in Table 4, a pooled estimate
of effect was calculated when a stricter inclu-
sion criterion was applied, namely, excluding
results from the study by Monteleone-Neto
et al. (1981). This had little influence on the
overall result, generating summary estimates of
0.97 (95% CI, 0.83–1.13) for the fixed effect
model or 0.93 (95% CI, 0.80–1.09) for the
random effect model. 
Cryptorchidism. Data for the six studies
included in the meta-analysis for cryp-
torchidism can be found in Table 5. The results
of only two studies significantly differ from
unity, as illustrated by the forest plot (Figure 3).
The small number of eligible studies renders
analysis of the funnel plot and potential for
publication bias difficult (Figure 4). The SEs
do, however, illustrate well that the studies were
all relatively small. No time trends for the esti-
mate of effect or the quality of studies could be
detected (not shown).
As presented in Table 6, the pooled esti-
mates of effect by both the Mantel–Haenszel
and DerSimonian–Laird methods are mar-
ginally superior to unity, and their relative
divergence implies there may be sources of
heterogeneity. Chi-square tests did not,
however, detect that any of the subsets were
significantly heterogeneous. Excluding studies
in which DES exposure was examined, either
exclusively or along with hormonal therapeutics,
yielded summary estimates consistent with no
relationship. Statistical pooling of the studies
including DES exposure generated a statisti-
cally significant estimate by the Mantel–
Haenszel method, suggesting a doubling of
the risk of cryptorchidism after in utero expo-
sure to DES. The same estimate by the
DerSimonian–Laird method did not, how-
ever, reach statistical significance and the dif-
ference relative to the fixed effect model is
indicative of heterogeneity. The heterogeneity
introduced by the DES subset of studies can
again be observed by comparing the results
obtained for all pharmaceutical estrogens with
those obtained by pooling the two studies of
accidental use of oral contraceptives during
pregnancy. Study design also appeared to be a
source of heterogeneity. If case–control studies
are prone to recall bias, this subset also
included the study with the highest estimate,
itself a source of heterogeneity, as shown by
the sensitivity analysis. Excluding the study by
Depue (1988) reduced the difference between
estimates by both models, the Mantel–
Haenszel estimate then calculated as 1.29
(95% CI, 0.87–1.91) and that by the
DerSimonian–Laird method as 1.23 (95% CI,
0.81–1.86). This was also observed for the
American subset of studies. When the Depue
(1988) study is omitted, the Mantel–Haenszel
method yielded a no longer statistically signifi-
cant estimate of 1.34 (95% CI, 0.84–2.14)
and the DerSimonian–Laird method an esti-
mate of 1.27 (95% CI, 0.72–2.23). 
Applying a stricter exclusion criterion to
studies examining hormonal treatment did
not affect which studies were included in the
meta-analysis of cryptorchidism. The study
with the highest weight appears to lower the
overall estimates, whereas increasing quality
seems to reduce heterogeneity and lower the
estimate of effect toward unity. These varia-
tions did not, however, influence the overall
conclusion that aside from the DES studies
subset, summary estimates did not detect any
association between in utero exposure to estro-
genic substances and cryptorchidism. 
Testicular cancer. Nine studies were
included in the meta-analysis of testicular can-
cer and the data used are summarized in
Testicular dysgenesis syndrome meta-analysis
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Table 4. RRs (95% CIs) of the summary estimate of effect, subsets, and sensitivity analyses for the associa-
tion between hypospadias and prenatal exposure to estrogenic agents.
No. of Mantel–Haenszel DerSimonian–Laird
studies method χ2 method
Subset of studies included (fixed effects) p-Value (random effects)
All studies 12 1.02 (0.88–1.19) 0.30 1.16 (0.83–1.62)
Excluding DES exposure 7 0.93 (0.79–1.09) 0.69 0.91 (0.78–1.07)
Studies including DES exposure 5 2.49 (1.54–4.02) 0.75 2.14 (1.15–3.98)
Mothers exposed to DES prenatally 3 3.73 (1.58–8.80) 0.40 2.54 (0.78–8.33)
Pharmaceutical estrogens only 9 1.85 (1.30–2.64) 0.45 1.54 (1.00–2.36)
Pharmaceutical estrogens excluding DES 4 1.27 (0.74–2.19) 0.36 1.13 (0.61–2.10)
Environmental estrogens only 3 0.90 (0.76–1.06) 0.89 0.90 (0.76–1.06)
European studies 4 0.96 (0.81–1.14) 0.18 0.96 (0.72–1.27)
North American studies 5 1.03 (0.63–1.68) 0.50 0.93 (0.56–1.55)
Latin American studies 2 1.86 (0.99–3.48) 0.39 1.78 (0.87–3.64)
Excluding highest risk ratio 11 1.00 (0.86–1.16) 0.37 0.99 (0.82–1.20)
Excluding lowest risk ratio 11 1.03 (0.87–1.20) 0.35 1.02 (0.84–1.25)
Excluding highest weight 11 1.55 (1.13–2.11) 0.42 1.29 (0.90–1.85)
Excluding lowest weight 11 1.00 (0.86–1.16) 0.37 0.99 (0.82–1.20)
Case–control studies only 8 0.98 (0.84–1.15) 0.22 1.00 (0.78–1.28)
Cohort studies only 4 2.10 (1.14–3.85) 0.54 1.46 (0.59–3.57)
Excluding studies with quality score < 30 7 0.94 (0.80–1.10) 0.85 0.93 (0.79–1.09)
Excluding studies with quality score < 35 5 1.11 (0.69–1.77) 0.83 1.06 (0.65–1.73)
Figure 3. Forest plot risk estimates and their
95% CIs from the studies included in the meta-
analysis of the association between prenatal expo-
sure to estrogenic agents and cryptorchidism.
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Figure 4. Funnel plot of the risk estimate studies
included in the meta-analysis of the association
between prenatal exposure to estrogenic agents
and cryptorchidism and their SEs.
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Table 5. Summary of data used for the meta-analysis of the association between prenatal estrogenic agents and cryptorchidism.
Cases Controls
References Design Agent Location E NE E NE RR (95% CI) SE Weight Quality score
Beard et al. 1984 Case–control Estrogenic drugs Minnesota, USA 9 104 15 211 2.20 (0.70–7.20) 0.47 4.60 34
Bhatia et al. 2005 Case–control DDT California, USA 11 32 42 117 0.95 (0.43–2.07) 0.39 6.65 41
Depue 1988 Case–control Estrogenic drugs United States 5 380 3 765 5.15 1.01 0.99 29
Harlap et al. 1985 Cohort Oral contraceptives North Carolina, USA 6 196 844 27,595 1.10 (0.10–3.90) 0.42 5.78 36
McBride et al. 1991 Case–control Oral contraceptives British Columbia, Canada 18 226 34 454 1.10 0.31 10.50 38
Vessey et al. 1983 Clinical trial DES United Kingdom 6 6 138 126 0.91 0.58 3.00 18
Abbreviations: E, exposed; NE, nonexposed.
Table 7. Of these, 4 had not been included in
the summary estimate previously calculated by
Toppari et al. (1996). The lack of homogene-
ity between studies is evident from the forest
plot (Figure 5). Further, the funnel plot
(Figure 6) also illustrates the relatively small
size of the included studies. Although a posi-
tive trend over time was found for the quality
of the included studies (Figure 7), no signifi-
cant time trend could be detected for the
effect size (not shown).
Both the fixed and random effect models
yield a statistically significant estimate; how-
ever, the discrepancy between the two results
is suggestive of heterogeneity despite the result
from the chi-square test (Table 8). Conversely,
the subset analysis was limited by the similar-
ity of the question addressed by the studies
included. Eight of the nine studies were inter-
ested in hormonal exposure and were con-
ducted in the United States. Despite this,
statistically significant heterogeneity between
the studies was detected at the 0.1 level.
Pooling the two studies examining DES expo-
sure specifically produced a raised but statisti-
cally nonsignificant result. Despite the
unexplained heterogeneity, all estimates that
were calculated point to a doubling of the risk
of developing testicular cancer after exposure
to estrogenic agents in utero. The work on
chlorinated biphenyls (PCBs) by Hardell et al.
(2004) was the only study examining environ-
mental estrogens. Its size was relatively small,
and it did not detect such an effect.
Applying a stricter exclusion criterion to
studies examining hormonal treatment
excluded four studies from the meta-analysis;
namely, Brown et al. (1986), Gershman and
Stolley (1988), Henderson et al. (1979), and
Weir et al. (2000). This resulted in a slightly
lower Mantel–Haenszel estimate of 1.98
(95% CI, 1.23–3.18) and if the DerSimonian–
Laird estimate remained equal to 1.59, because
of the wider confidence interval (95% CI,
0.93–2.69), statistical significance was no
longer achieved. The sensitivity analysis is con-
sistent with some heterogeneity between the
studies, the estimates obtained being relatively
sensitive to the exclusion of particular studies
varying above and below a risk estimate of 2.
The quality of the studies seemed to explain at
least some of this heterogeneity.
Discussion
While it is clear that hypospadias, crypt-
orchidism, and testicular cancer are all posi-
tively associated with prenatal exposure to
DES, this meta-analysis was unable to produce
evidence that such effects were associated with
environmental estrogens or even accidental use
of oral contraceptives during pregnancy. This
is consistent with the results obtained in earlier
meta-analyses (Raman-Wilms et al. 1995;
Toppari et al. 1996).
The main limitations of meta-analysis are
a) the susceptibility of its summary results to
publication bias, b) the influence of the quality
of studies, c) the possibility of including multi-
ple results from the same study, and finally,
d) heterogeneity between studies that could
lead to invalid conclusions. The methodology
employed in this present review attempts to
address these issues. Additionally, the impor-
tance of carrying out and reporting a sensitivity
analysis was illustrated by the case of hypospa-
dias where the weight attributed to one partic-
ularly large study had a nonnegligible influence
on the results. In this particular case, the study
by Vrijheid et al. (2003) inferred exposure to
phthalates from registry data about occupation,
and although such an approach can allow the
analysis of a great number of cases, assessment
of exposure is much more likely to be prone to
confounding. The number of studies included
in meta-analyses lies typically between 5 and
15, and the results presented here also fall
within this range. The size of the homogeneity
test statistic depends on both the number and
size of individual studies. The funnel plots
offer a good visual representation of the preci-
sion and size of individual studies, and it is
clear that most studies published on the associ-
ation between estrogenic agents and the proba-
ble end points of a TDS were found to be
relatively small. The chi-square tests had, there-
fore, a relatively low power to detect hetero-
geneity. However, in the absence of statistical
Martin et al.
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Table 7. Summary of data used for the meta-analysis of the association between prenatal estrogenic agents and testicular cancer.
Cases Controls Quality
Reference Design Agent Location E NE E NE RR (95% CI) SE Weight score
Brown et al. 1986 Case–control Sex hormones Washington, DC, USA 4 198 5 201 0.80 (0.20–3.50) 0.64 2.43 30
Depue et al. 1983 Case–control Estrogenic drugs Los Angeles, USA 8 88 2 103 8.00 (1.30–49) 1.07 0.88 32
Gershman and Stolley 1988 Case–control DES Connecticut, USA 4 75 5 74 0.80 (0.10–4.50) 0.65 2.37 22
Hardell et al. 2004 Case–control Estrogenic PCBs Sweden 29 29 30 31 1.30 (0.50–3.00) 0.37 7.31 39
Henderson et al. 1979 Case–control Hormone treatment Los Angeles, USA 6 72 1 77 5.00 1.47 0.46 29
Moss et al. 1986 Case–control DES or other hormones California and 7 202 6 204 0.90 (0.30–2.60) 0.59 2.89 34
Nevada, USA
Schottenfeld et al. 1980 Case–control DES or other hormones United States 11 170 3 133 3.05 0.79 1.61 26
Strohsnitter et al. 2001 Cohort DES United States 6 2 1,359 1,392 3.05 (0.65–21.96) 1.01 0.99 37
Weir et al. 2000 Case control Hormone treatment Ontario, Canada 15 310 7 483 4.90 (1.70–13.90) 0.61 2.66 40
Abbreviations: E, exposed; NE, nonexposed.
Table 6. RRs and 95% CIs of the summary estimate, subsets and sensitivity analyses for the association
between cryptorchidism and prenatal exposure to estrogenic agents.
No. of Mantel–Haenszel DerSimonian–Laird
studies method χ2 method
Subset of studies included (fixed effects) p-Value (random effects)
All studies 6 1.34 (0.96–1.87) 0.44 1.22 (0.86–1.73)
Excluding DES exposure 3 1.06 (0.70–1.59) 0.95 1.05 (0.70–1.59)
Studies including DES 3 2.09 (1.13–3.86) 0.24 1.80 (0.83–3.93)
Pharmaceutical estrogens 5 1.44 (0.99–2.10) 0.37 1.31 (0.87–1.96)
Pharmaceutical extrogens excluding DES 2 1.10 (0.49–2.49) 1 1.10 (0.49–2.49)
Case–control studies 4 1.45 (0.98–2.15) 0.24 1.38 (0.81–2.34)
Cohort studies 2 1.04 (0.53–2.02) 0.79 1.03 (0.53–2.00)
American studies 4 1.55 (1.00–2.39) 0.24 1.40 (0.82–2.41)
Excluding highest risk ratio 5 1.21 (0.86–1.72) 0.66 1.16 (0.81–1.66)
Excluding lowest risk ratio 5 1.38 (0.97–1.97) 0.34 1.27 (0.86–1.87)
Excluding highest weight 5 1.46 (0.97–2.19) 0.32 1.30 (0.82–2.06)
Excluding lowest weight 5 1.21 (0.86–1.72) 0.66 1.16 (0.81–1.66)
Excluding studies with quality score < 30 4 1.25 (0.86–1.80) 0.53 1.19 (0.82–1.73)
Excluding studies with quality score < 35 3 1.06 (0.70–1.59) 0.95 1.05 (0.70–1.59)
Figure 5. Forest plot risk estimates and their 95% CIs
from the studies included in the meta-analysis of the
association between prenatal exposure to estro-
genic agents and testicular cancer.
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heterogeneity, the results of the fixed effect and
random effect models should be virtually iden-
tical, and the comparison of results obtained by
applying both the Mantel–Haenszel and
DerSimonian–Laird models enabled the explo-
ration of sources of heterogeneity despite this
low statistical power. 
If the quality of the studies was found to
explain some of the heterogeneity observed,
particularly in the case of testicular cancer,
the remaining heterogeneity could not be
explained solely by the fact that environmental,
and therefore generally much weaker, estrogens
were included in the analysis. The systematic
review of published literature yielded relatively
few studies examining the association of male
urogenital abnormalities or testicular cancer
with environmental estrogens specifically; a
number of studies concerned with an asso-
ciation with broad categories of putative
endocrine disruptor, most often pesticides,
were excluded from the meta-analyses. This
illustrates the difficulties associated with assess-
ment of exposure, pesticide exposure often
being inferred from parental occupation rather
than direct measurement. Furthermore, there
is increasing evidence that, in accordance with
pharmacokinetic theory, the effects of xeno-
biotics acting via the same mechanism can be
predicted fairly accurately by concentration
addition (Zhu et al. 2006). Accurately
accounting for combined exposure or adjusting
for the confounding introduced by environ-
mental exposures will probably require the
development of mechanism-specific bio-
markers of exposure. 
When DES is excluded, there is no con-
clusive evidence of an effect of pharmaceutical
estrogens. Exposure to such estrogens is
related mainly to the accidental use of oral
contraceptives during pregnancy or hormonal
pregnancy tests. Such estrogenic pharmaceuti-
cals often are given in combination with prog-
estagens, and it is legitimate to question
whether unopposed estrogens would have the
same effects as opposed estrogens. This also
highlights another difficulty associated with
exposure assessment, that of critically sensitive
periods of development and the ascertainment
of whether exposure took place during a “win-
dow” of susceptibility to hormone disruption.
Nonetheless, studies in which maternal levels
of hormones were measured in the first and
third trimester of pregnancy do not support
an association with elevated estrogen levels but
rather indicate that a lower estrogen/androgen
ratio and/or higher levels of α-fetoproteins
may be beneficial (McGlynn et al. 2005;
Zhang et al. 2005). If in animals both estro-
genic and antiandrogenic compounds have
been associated with end points consistent
with those of human TDS (Fisher 2004;
Veeramachaneni 2000), epidemiologic evi-
dence remains elusive. Alternatively, the dou-
bling of the risk estimates of all three effects
associated with DES exposure would be consis-
tent with a shared etiology and the TDS
hypothesis. It does not constitute conclusive
evidence of an estrogenic mode of action, how-
ever, as common etiologic factors could be
related to the underlying condition for which
DES was prescribed. Furthermore hypospa-
dias, cryptorchidism, and testicular cancer have
all been found to be associated with low birth
weight, suggesting a potential association with
an underlying placental defect. 
The understanding of the importance of
endogenous estrogens in normal adult testicular
function is becoming clearer. Their roles during
fetal life, however, remain relatively unclear, but
those mediated by the ER-α or ER-β have
been shown to differ (Habert et al. 2006).
Interestingly, DES has been found to have sim-
ilar affinity for both receptors, whereas estradiol
has only a slightly stronger affinity for ER-α
compared with ER-β (Mueller et al. 2004).
ER-α has been detected in undifferentiated
gonads as early as 10 days postconception in the
mouse and found to be localized in the Leydig
cells of fetal testis in rodents (Habert et al.
2006). Studies of the expression of ER-α and
ER-β in human and nonhuman primates have
so far yielded inconsistent results. Gaskell et al.
(2003) reported that ER-α could not be
detected in human fetal testes between weeks
12–19 of gestation, whereas Shapiro et al.
(2005) found that ER-α was apparent by
week 12, its levels peaked at 16 weeks before
diminishing, and it was localized in Leydig
cells. Current research focus has shifted to the
role played by testosterone, anti-Müllerian hor-
mone and insulin-like factor 3 produced by the
fetal testes during masculinization. In the male
rat, exposure to high levels of estrogens has
been shown not only to suppress testosterone
production but also to downregulate the expres-
sion of the androgen receptor protein in repro-
ductive target tissues including the testes,
Wolffian duct, and prostate (Sharpe 2006).
Further research in this area may help shed light
on possible mechanisms of injury or relevance
of the rodent model.
The subset analyses did not generate many
clues to explain the heterogeneity of the col-
lected data. This is, however, consistent with
the wide geographic variability in the incidence
of the conditions of interest (Boisen et al. 2004;
Richiardi et al. 2004). Interactions between
genetic susceptibility and the environment have
been the focus of research in this area (Martin
et al. 2007), and advances in genomics have
allowed the identification of polymorphisms
associated with hypospadias, cryptorchidism,
and testicular cancer (Beleza-Meireles et al.
2006; Kurahashi et al. 2005; Starr et al. 2005;
Yoshida et al. 2005). Such discoveries may,
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Table 8. RRs and 95% CIs of the summary estimates, subsets and sensitivity analyses for the association
between testicular cancer and prenatal exposure to estrogenic agents.
No. of Mantel–Haenszel DerSimonian–Laird
studies method χ2 method
included (fixed effects) p-Value (random effects)
All studies 9 2.14 (1.48-3.10) 0.12 1.59 (1.04–2.43)
DES exposure exclusively 2 2.53 (0.79–8.09) 0.77 2.47 (0.61–10.00)
Pharmaceutical estrogens 8 2.57 (1.66–3.99) 0.09 1.94 (0.98–3.87)
Case–control studies only 8 2.10 (1.43–3.07) 0.09 1.71 (0.92–3.17)
North American studies 8 2.57 (1.66–3.99) 0.09 1.94 (0.98–3.87)
Excluding highest risk ratio 8 1.89 (1.29–2.78) 0.21 1.56 (0.93–2.61)
Excluding lowest risk ratio 8 2.31 (1.56–3.40) 0.14 1.94 (1.08–3.48)
Excluding highest weight 8 2.57 (1.66–3.99) 0.09 1.94 (0.98–3.87)
Excluding lowest weight 8 2.08 (1.42–3.03) 0.10 1.68 (0.95–2.97)
Excluding studies with quality score < 30 6 2.16 (1.42–3.29) 0.08 1.79 (0.91–3.52)
Excluding studies with quality score < 35 3 2.33 (1.39–3.91) 0.13 2.23 (0.98–5.05)
Figure 6. Funnel plot of the risk estimate studies
included in the meta-analysis of the association
between prenatal exposure to estrogenic agents
and testicular cancer and their SEs.
0.10 1.00 10.00
Risk ratio
St
an
da
rd
 e
rr
or
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Figure 7. Time trend for quality showing quality
score attributed to studies included in the meta-
analysis of the association between prenatal expo-
sure to estrogenic agents and testicular cancer by
year of publication. R2 = 0.5711.
1975 1980 1985 1990 1995 2000 2005 2010
45
40
35
30
25
20
Q
ua
lit
y 
sc
or
e
Year of publication
however, give rise to as many questions as they
offer to answer. This is well illustrated by the
recent identification of the association of a vari-
ant of the gene for the ER-α with hypospadias
and cryptorchidism in Japanese cohorts
(Watanabe et al. 2007; Yoshida et al. 2005)
that has now been found to be associated with a
decreased incidence of hypospadias in a
European cohort (Galan et al. 2007). 
Conclusion
The modest increase in risk for all three end
points associated with DES exposure is consis-
tent with a shared etiology and the TDS
hypothesis, whereas the results of the subset
analyses suggest the existence of yet unidenti-
fied sources of heterogeneity between studies or
within the study populations. Although
10 years of further research on the potential
effects of endocrine disruptors on male repro-
ductive health have provided some clues regard-
ing the etiology and mechanism of conditions
such as hypospadias, cryptorchidism, and testic-
ular cancer, there is still no conclusive evidence
of the role played by environmental estrogens.
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